Reported Earlier, Avidity Biosciences Prices $400.9M Public Offering Of 10.55M Common Shares At $38/Share

All of the shares to be sold in the offering are to be sold by Avidity. The gross proceeds to Avidity from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be $400.9 million. The offering is expected to close on or about June 17, 2024, subject to the satisfaction of customary closing conditions